Summary & Overview
CPT 0452U: EarlyTect® Bladder Cancer Detection, PENK Methylation Urine Assay
CPT code 0452U identifies a proprietary molecular diagnostic assay — EarlyTect® Bladder Cancer Detection — that measures methylated PENK DNA in urine via LTE–qMSP and reports the likelihood of bladder cancer. As a PLA code, 0452U applies uniquely to Promis Diagnostics Inc.'s test and signals an advanced, manufacturer-specific laboratory service that may affect coding, billing, and coverage reviews nationwide. The code matters because urine-based methylation assays offer a noninvasive option for bladder cancer detection and can influence diagnostic pathways and utilization of molecular diagnostics across health plans.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, payer coverage considerations, and typical service and site-of-service context. The publication summarizes national benchmarking and policy implications for a PLA-coded molecular diagnostic, highlights clinical context for PENK methylation as a bladder cancer biomarker, and notes where input data are not available. This resource is intended for coding and reimbursement professionals, laboratory managers, and clinicians seeking a clear national-level summary of CPT code 0452U and its role in bladder cancer diagnostic services.
Billing Code Overview
CPT code 0452U is a Proprietary Laboratory Analyses (PLA) code for EarlyTect® Bladder Cancer Detection (EarlyTect® BCD), manufactured by Promis Diagnostics Inc. The test analyzes a urine specimen using linear target enrichment–quantitative methylation–specific real–time PCR (LTE–qMSP) to detect methylated PENK DNA. Results are reported as the likelihood of bladder cancer based on PENK methylation, a biomarker associated with bladder cancer.
Service Type: Proprietary molecular diagnostic laboratory test (urine-based methylation assay)
Typical Site of Service: Clinical laboratory or specialized molecular diagnostics laboratory; sample collected in outpatient settings
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of tobacco use presents to urology with painless gross hematuria and intermittent urinary frequency. The urologist orders the EarlyTect® Bladder Cancer Detection test (report with CPT code 0452U) on a voided urine specimen to assess the likelihood of bladder cancer using methylated PENK DNA detected by LTE–qMSP. Specimen collection occurs in the outpatient clinic or an affiliated phlebotomy/laboratory draw site; the sample is sent to the manufacturer's designated laboratory for proprietary testing. Results are returned as a probability or likelihood of bladder cancer and are used alongside cystoscopy, urine cytology, and imaging to guide decisions such as performing diagnostic cystoscopy, biopsy, or surveillance scheduling. Typical workflow: patient presents → clinician documents indication (hematuria, surveillance of prior urothelial carcinoma, or suspicious urine cytology) → voided urine specimen collected and labeled → specimen shipped per manufacturer instructions to the performing lab → laboratory performs LTE–qMSP for PENK methylation → report issued to ordering clinician, who documents interpretation and next-step plan in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier used / default | Use when no additional modifier applies to the service |
22 | Increased procedural services | Use when there is documentation of substantially greater work or complexity in specimen handling or reporting beyond standard test processing |
26 | Professional component | Use when billing for the physician or pathologist professional interpretation portion separate from the performing lab technical component (if applicable) |
52 | Reduced services | Use when the test is partially performed or limited due to inadequate specimen or preanalytic issues |
53 | Discontinued service | Use when testing was started but stopped for documented reasons prior to completion |
62 | Two surgeons / multiple practitioners | Rare for this lab test; use only if two distinct practitioners with separate roles bill for professional interpretation |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure | Not typically applicable; include only if a related invasive procedure required immediate repeat intraoperative testing |
80 | Assistant surgeon | Not applicable for a lab-based test; use only in unusual workflow where an assistant bills separately for professional work |
82 | Assistant not available | As above, only in exceptional billing situations for professional services |
TC | Technical component | Use when billing solely for the laboratory technical component of the test (common for PLA tests performed by a reference lab) |
QX | Ordering/testing physician services furnished under a mutually exclusive arrangement | Use when applicable to denote specific contractual arrangements per payer policy |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
208000000X | Urology | Urologists commonly order this urine-based bladder cancer detection test |
207P00000X | Pathology | Pathologists may interpret molecular assay results and provide consultative reports |
208D00000X | Diagnostic Radiology | Radiologists involved in imaging correlation and staging may reference test results |
363L00000X | Clinical Laboratory | Clinical laboratory specialists/directors oversee specimen processing and result verification |
207L00000X | Anatomic and Clinical Pathology | Physicians in anatomic/clinical pathology interpret and integrate molecular diagnostics |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
R31.0 | Gross hematuria | Hematuria is a common indication to order bladder cancer detection testing |
R31.9 | Hematuria, unspecified | Used when hematuria is present but not further specified; justifies noninvasive urine testing |
N13.6 | Pyuria | May be evaluated concurrently; differentiates infectious causes from neoplastic causes when interpreting urine tests |
N28.9 | Disorder of kidney and ureter, unspecified | Used when hematuria or urinary symptoms are attributed to upper tract until bladder cancer is excluded |
C67.9 | Malignant neoplasm of bladder, unspecified | Known or suspected bladder cancer — test used for surveillance or diagnostic clarification |
Z85.51 | Personal history of malignant neoplasm of bladder | Surveillance testing for recurrence in patients with prior bladder cancer |
R39.15 | Urgency of urination | Lower urinary tract symptoms that may accompany bladder pathology and prompt testing |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0452U | EarlyTect® Bladder Cancer Detection (PENK methylation) — LTE–qMSP on urine, proprietary laboratory analysis | Primary PLA code for the specific urine methylation assay used to report likelihood of bladder cancer |
88112 | Cytopathology, limited to single cell type, urine cytology (non-gynaecological) | Often performed alongside urine-based molecular testing to evaluate for malignant cells prior to or concurrent with 0452U |
88377 | Flow cytometry, each additional marker, interpretation and report | Ancillary laboratory testing such as flow cytometry may be used in select urothelial malignancy workups complementary to molecular assays |
52000 | Cystourethroscopy, with or without collection of specimen(s) by brushing or washing | Diagnostic cystoscopy is commonly performed before or after urine-based testing to visualize lesions and obtain biopsies |
52204 | Cystourethroscopy, with biopsy(s) | Biopsy for histologic confirmation follows positive or suspicious noninvasive tests including molecular assays |
88305 | Pathology examination of tissue, gross and microscopic, routine surgical pathology | Histopathologic evaluation of biopsy specimens obtained after a positive urine molecular test |